Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Apr 05, 2019 9:37am

122 Views

Post# 29586718

RE:RE:RE:Weekly Trogarzo Sales - looking good

Thanks.

What do they have for peak sales for Egrifta and Trogarzo?

Hard to predict Egrifta given the NASH angle but Luc has always guided towards $200-250 million peak for Trogarzo.

bfw

1998novl wrote: Canaccord analyst was upbeat and remains the most focused in trying to capture the reality of the company’s prospects. RBC is turning a bit more positive but generally thinks the stock price reflects peak sales for EGRIFTA and TROGARZO. Hopefully we can get another US analyst on the case or even RBC, TD or BMO in Canada.

Bullboard Posts

How one company is disrupting PoC testing